Recently, emerging evidence has suggested that glucagon-like peptide-1 (GLP-1) could be a candidate for treating intestinal-related diseases such as IBD, intestinal mucositis, coeliac disease and SBS. Here, GCG is linked to inflammatory bowel disease.